Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — NYC Builds Bio+ Vanquishing the Virus (May 2020)

11 slides from Tonix Pharmaceuticals's conference presentation, May 15, 2020

  1. Slide 1: NYC Builds Bio+ Vanquishing the Virus

    © 2020 Tonix Pharmaceuticals Holding Corp. 1 May 19, 2020 1 – 2 pm Version P0231 5 - 19 - 20 (Doc 0631) NYC Builds Bio+ Vanquishing the Virus

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    © 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat

  3. Slide 3: Potential COVID-19 Vaccine TNX-1800

    © 2020 Tonix Pharmaceuticals Holding Corp. 3 Potential COVID - 19 Vaccine 1 TNX - 1800 (modified horsepox virus) 2,3 • Pre - clinical and pre - IND stage • Live virus vaccine designed on our horsepox vaccine platform 4 to express the SARS - CoV - 2 Spike (S) protein • Milestones: • 4 th Quarter 2020

  4. Slide 4: Considerations in SARS-CoV-2 Vaccination Strategies: Choice of Antigen

    © 2020 Tonix Pharmaceuticals Holding Corp. 4 Considerations in SARS - CoV - 2 Vaccination Strategies: Choice of Antigen • CoVs are characterized by spike (S) proteins projecting from the virion surface 1 • Antibodies generated against S proteins in SARS - CoV provide full protection against infectio

  5. Slide 5: TNX-1800 Based on a Horsepox Virus Vector Designed to Express SARS-CoV-2 S Protein

    © 2020 Tonix Pharmaceuticals Holding Corp. 5 TNX - 1800 is Based on a Horsepox Virus (HPXV) Vector Designed to Express SARS - CoV - 2 S Protein *TNX - 1800 is at the pre - IND stage of development Horsepox sHPXV ~200,000 Bp Homologous Recombination TNX - 1800 * rHPXV/SARS - CoV - 2S ~200,000 Bp

  6. Slide 6: The TH1/TH2 Decision: Immune System Chooses Cellular or Humoral Response

    © 2020 Tonix Pharmaceuticals Holding Corp. 6 CD8 T cell Antibodies CD4 T cell B cell The T H 1/T H 2 Decision: The Immune System Chooses a Cellular or Humoral Response • T H 1 (cellular) and T H 2 (humoral) responses are characterized by unique cytokine patterns 1,2 • The immune response favors T H

  7. Slide 7: Advantages of Live, Replicating HPXV as a Vector Platform for Vaccines

    © 2020 Tonix Pharmaceuticals Holding Corp. 7 Advantages of Live, Replicating HPVX as a Vector Platform for Vaccines • TNX - 1800 – infected host cells are designed to produce SARS - CoV - 2 S protein, activating an immune response against those proteins • TNX - 1800 is based on a live, replicating v

  8. Slide 8: TNX-1800 Is Designed to Induce Robust TH1 Cellular Immunity

    © 2020 Tonix Pharmaceuticals Holding Corp. 8 TNX - 1800 is Designed to Induce Robust T H 1 Cellular Immunity 1. Fulginiti VA, et al. Clin Infect Dis. 2003;37(2):241 - 250. 2. Liu L, et al. Nature Med. 2010;16(2):224 - 228. 3. Centers for Disease Control and Prevention. Accessed April 15, 2020. https

  9. Slide 9: Relationship Between Horsepox, Certain Vaccinia Strains and Variola

    © 2020 Tonix Pharmaceuticals Holding Corp. 9 Relationship Between Horsepox, Certain Vaccinia Strains and Variola Legend: Alignment of orthopoxvirus genomes and location of horsepox (HPXV) genes within telomeres. Orthopoxvirus genomes were aligned using the program GView ( https://server.gview.ca ).

  10. Slide 10: Development of TNX-1800 as a COVID-19 Vaccine: Collaboration with Southern Research

    © 2020 Tonix Pharmaceuticals Holding Corp. 10 Development of TNX - 1800 as a COVID - 19 Vaccine Collaboration with Southern Research • Southern Research will develop and test TNX - 1800, which is designed to express Spike (S) protein from the virus that causes COVID - 19, which is called SARS - CoV

  11. Slide 11: Thank you!

    © 2020 Tonix Pharmaceuticals Holding Corp. 11 Thank you ! NASDAQ: TNXP

Tonix Pharmaceuticals Holding — NYC Builds Bio+ Vanquishing the Virus (May 2020) on 6ix